Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Starting from previous observations emphasizing an increased pseudocholinesterase (PCE) activity in obese and hyperlipemic subjects, the behaviour of this enzyme and of ceruloplasmin was studied in connection with changes of serum lipids and lipoproteins in various types of hyperlipoproteinemia. When compared to values detected in 67 middle-aged normal weight normolipemic subjects, PCE activity was found to be significantly greater (smaller than 0.001) in the 49 overweight subjects without obvious hyperlipemia but presenting a moderate increase of the prebeta electrophoretic fraction. PCE activity was much higher in lean or overweight subjects with endogenous hypertriglyceridemia (68 patients with type IV and 86 patients with mixed hyperlipemia). The slight increase of mean values of PCE activity in the 53 subjects with type II-a was due mainly to overweight subjects, while this enzyme's activity was not significantly changed in lean subjects with pure hypercholesterolemia. PCE activity was positively correlated with serum triglyceride (r equals 0.540; p smaller than 0.001) and the prebeta electrophoretic fraction (r equals 610; p smaller than 0.001). The correlation with beta-lipoproteins was not significant. Ceruloplasmin levels were not significantly changed. It is suggested that elevation of PCE activity could be connected to mechanisms leading to an increased secretion rate of lipoproteins.
 ...
PMID:Serum pseudocholinesterase and ceruloplasmin in various types of hyperlipoproteinemia. 16 6

This study was designed to monitor the metabolic differences after feeding starch, galactose and fructose diets with adequate or marginal copper levels to normal male rats over a period of 9-21 months. Two hundred and forty-five weanling male Sprague-Dawley rats weighing approximately 50-60 g were randomly divided into one of the eight dietary groups. All diets were either Cu marginal (1.5 &mgr;g/g diet) or adequate (5-6 &mgr;g/g) with 627 carbohydrate (g/kg diet) as starch; 500 galactose and 127 starch; 500 fructose and 127 starch; or 400 galactose and 227 fructose. Glycated hemoglobin, ceruloplasmin oxidase activity, hematocrit, and plasma glucose, cholesterol, and triglyceride were measured in 72 rats after nine months. Galactose-fed rats had the lowest (P < 0.0001) body weights. Severe mortality rates were found in galactose-fructose-marginal Cu-fed rats. Marginal Cu deficiency significantly (P < 0.0001) reduced hepatic copper and increased hepatic Fe in all carbohydrate groups. Ceruloplasmin activity of the rats fed the marginal Cu and fructose-containing diets declined to undetectable levels and plasma cholesterol levels increased. Glycated hemoglobin was significantly (P < 0.001) increased in the galactose-fed rats compared to fructose or starch-fed rats regardless of dietary copper concentration. The data suggest that dietary galactose and fructose exacerbate effects of long term marginal Cu intake including hypertrophy of liver, heart and kidney, hyperlipidemia, and increased mortality.
 ...
PMID:Effects of dietary galactose and fructose on rats fed diets marginal or adequate in copper for 9-21 months. 1144 91